We are live on
!
Find out more
OM
Opaleye Management Portfolio holdings
AUM
$1.1B
Turnover
32.84%
1-Year Est. Return
197.64%
This Fund
S&P 500
This Quarter
Est. Return
+22.36%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.69%
AUM
$386M
AUM Growth
+$36.6M
(+10%)
Cap. Flow
-$1.12M
Cap. Flow
% of AUM
-0.29%
Top 10 Holdings %
Top 10 Hldgs %
62.47%
Holding
49
New
11
Increased
11
Reduced
7
Closed
13
Avg Time Held
1.1
years
Top 10 Avg Time Held
1
year
Top 20 Avg Time Held
1.1
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PTE
PolarityTE, Inc. Common Stock
PTE
|
+$19M |
| 2 |
AMAG
AMAG Pharmaceuticals
AMAG
|
+$9.29M |
| 3 |
Viridian Therapeutics
VRDN
|
+$8.46M |
| 4 |
Dianthus Therapeutics
DNTH
|
+$7.76M |
| 5 |
Xencor
XNCR
|
+$6.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Blueprint Medicines
BPMC
|
+$19.9M |
| 2 |
Axogen
AXGN
|
+$12.1M |
| 3 |
Ardelyx
ARDX
|
+$5.73M |
| 4 |
ABLX
Ablynx NV
ABLX
|
+$4.91M |
| 5 |
ACHN
Achillion Pharmaceuticals
ACHN
|
+$4.06M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
DELISTED
Apellis Pharmaceuticals
APLS
| $5.83M | 1.51% |
+265,000
| New | +$6.09M |
2018 Q2
0 quarters
|
|
27
DELISTED
Chimerix, Inc.
CMRX
| $5.47M | 1.42% |
1,150,000
+550,000
| +92% | +$2.63M |
2016 Q1
9 quarters
|
|
28
Amarin Corp
AMRN
$244M
| $5.41M | 1.4% |
87,500
+250
| +0.3% | +$15.5K |
2017 Q4
2 quarters
|
|
|
BFRA
29
DELISTED
Biofrontera AG American Depositary Shares
BFRA
| $4.75M | 1.23% |
+391,400
| New | +$5.3M |
2018 Q2
0 quarters
|
|
|
FOMX
30
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $3.83M | 0.99% |
250,000
-700,000
| -74% | -$3.6M |
2015 Q2
12 quarters
|
|
|
EPZM
31
DELISTED
Epizyme, Inc
EPZM
| $3.73M | 0.96% |
275,000
+205,000
| +293% | +$3.19M |
2018 Q1
1 quarter
|
|
|
ARQL
32
DELISTED
Arqule Inc
ARQL
| $2.32M | 0.6% |
+420,000
| New | +$1.6M |
2018 Q2
0 quarters
|
|
33
Protalix BioTherapeutics
PLX
$218M
| $1.33M | 0.35% |
310,000
-16,000
| -5% | -$71.1K |
2017 Q4
2 quarters
|
|
|
CTIC
34
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $803K | 0.21% |
+161,400
| New | +$706K |
2018 Q2
0 quarters
|
|
35
GridAI Technologies Corp
GRDX
$33.3M
| $417K | 0.11% |
+1
| New | +$369K |
2018 Q2
0 quarters
|
|
36
BioLineRX
BLRX
$10.2M
| $222K | 0.06% |
417
| – | – |
2013 Q4
18 quarters
|
|
|
37
Ardelyx
ARDX
$855M
| – | – |
-1,135,600
| Closed | -$5.73M | – |
|
38
DELISTED
Assertio
ASRT
| – | – |
-10,000
| Closed | -$3.95M | – |
|
39
Fortress Biotech
FBIO
$64.7M
| – | – |
-21,000
| Closed | -$1.43M | – |
|
40
Quanterix
QTRX
$142M
| – | – |
-150,000
| Closed | -$2.56M | – |
|
41
Syndax Pharmaceuticals
SNDX
$1.21B
| – | – |
-222,500
| Closed | -$3.17M | – |
|
42
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| – | – |
-7,407
| Closed | -$961K | – |
|
|
QTNT
43
DELISTED
Quotient Limited Ordinary Shares
QTNT
| – | – |
-1,500
| Closed | -$282K | – |
|
|
ZSAN
44
DELISTED
Zosano Pharma Corporation
ZSAN
| – | – |
-2,857
| Closed | -$504K | – |
|
|
ACHN
45
DELISTED
Achillion Pharmaceuticals
ACHN
| – | – |
-1,095,100
| Closed | -$4.06M | – |
|
|
ABLX
46
DELISTED
Ablynx NV
ABLX
| – | – |
-90,000
| Closed | -$4.91M | – |
|
Similar funds
CFO
PFM
HBCM
AI
TPA
ZDA
NW
TFA
Opaleye Management's Q2 2018 Portfolio in Review
As of Q2 2018, Opaleye Management held 49 positions worth $386M, up 10% from $350M the previous quarter. Its ten largest holdings account for 62% of the portfolio.
Opaleye Management's Q2 2018 filing shows 11 new, 11 increased, 7 reduced and 13 closed positions. Its largest new stake was PolarityTE, Inc. Common Stock: 32,000 shares worth $18.8M. The largest sale was Blueprint Medicines, an estimated $19.9M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 94% a quarter earlier.
- Opaleye Management's largest Q2 2018 buy was PolarityTE, Inc. Common Stock: 32,000 shares worth $18.8M.
- Opaleye Management added most to TG Therapeutics in Q2 2018, an estimated $4.82M increase.
- Opaleye Management's biggest Q2 2018 reduction was Blueprint Medicines, cutting an estimated $19.9M.
- Opaleye Management fully exited Ardelyx in Q2 2018, selling an estimated $5.73M.
- Opaleye Management's ten largest holdings make up 62% of its $386M portfolio in Q2 2018.
- Opaleye Management opened 11 new positions and closed 13 in Q2 2018.
- Opaleye Management's portfolio value rose 10% quarter-over-quarter to $386M.
Based on Opaleye Management's 13F filing for Q2 2018, filed 14 Aug 2018.